|
Permitting large-scale clinical study integrating Ayurveda with modern TB treatment a landmark step: expert
|
|
Nandita Vijayasimha, Bengaluru
April 01 , 2026
|
|
|
Government of India’s decision to permit a large-scale clinical study integrating Ayurveda with modern treatment for tuberculosis marks a landmark step in bridging traditional and contemporary healthcare system, said Dr R Govindarajan chief innovation officer, Kapiva.
This initiative is not merely about providing 'alternative' care but it is about establishing measurable, adjunctive therapies that can fundamentally improve nutritional outcomes and slow disease progression. It signals a larger, systemic shift from cultural preservation to clinical utility. When the state commits to registering traditional interventions in the global clinical evidence base, it institutionalises trust for both the medical community and patients simultaneously. This creates a definitive blueprint for India to emerge as the global case study in integrative healthcare. By systematically combining the acute precision of allopathy with the preventive and restorative strengths of traditional systems, we can offer a holistic, evidence-based medical model that the rest of the world can replicate, he added.
"Ayurveda in India is currently at a critical and transformative inflection point. For centuries, this ancient system of medicine operated primarily on inherited wisdom, passed down through generations and validated by centuries of empirical observation. While that foundational knowledge is undeniably profound, today’s global healthcare landscape demands a more rigorous framework. The modern patient, increasingly health-literate and discerning, expects the exact same protocol-driven clinical evidence from an Ayurvedic intervention as they do from a conventional pharmaceutical one. We are moving away from an era of anecdotal trust toward an era of clinical certainty”, Dr Govindarajan told Pharmabiz in an email.
Global precedents show us exactly where this path leads. Traditional Chinese Medicine (TCM), for instance, has grown into a market valued at over USD 250 billion today by successfully bridging the gap between tradition and modern science. A pivotal moment for TCM was when a traditional herbal treatment for malaria was subjected to rigorous clinical trials, eventually leading to a Nobel Prize in Medicine in 2015. This proved that traditional knowledge, when distilled through the lens of modern pharmacology, could solve global health crises, he said.
In the current ecosystem, driving research and development must be one of 'Radical Transparency. We must reimagine Ayurveda through a lens that prioritises standardisation, DNA authentication of botanicals, safety validation, and well-designed human clinical trials. Clinical evidence must no longer be viewed as an optional post-marketing luxury; it must become the very foundation of product development. The objective for the industry must be to create reproducible, high-quality outcomes that raise the overall evidence benchmark for the entire Ayurvedic ecosystem, he noted.
Ayurveda does not need to choose between its rich heritage and scientific credibility. In fact, when examined through rigorous scientific frameworks, traditional knowledge often finds its strongest validation. The real mandate for the Indian Ayurveda industry now is systematic, transparent, and scalable execution. By proving efficacy through data, we ensure that Ayurveda is not just a legacy of the past, but a pillar of the future of global medicine,” said Dr. Govindarajan.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|